Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 2NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Breast Neoplasms 61HER2-positive Breast Cancer 10Neoplasm Metastasis 5Ovarian Neoplasms 4Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Solid Tumor 2Prostatic Neoplasms 2Endometrial Neoplasms 2Brain Neoplasms 2Biliary Tract Neoplasms 2Urinary Bladder Neoplasms 1Solid Tumors 1Solid Cancers 1Solid Cancer 1Resectable HER2-positive Breast Cancer 1Recurrence 1Patient Preference 1Neoplasms, Unknown Primary 1Lung Neoplasms 1Liver Neoplasms 1Inflammatory Breast Neoplasms 1HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1HER2-positive Early Breast Cancer 1HER2-Positive Early Breast Cancer 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Early-stage or Locally Advanced HER2-positive Breast Cancer 1Early or Locally Advanced HER2-positive Breast Cancer 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × pertuzumab × Clear all
NCT01684878 2017-05-23

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

Hoffmann-La Roche

Phase 3 Completed
208 enrolled 19 charts
Gynecologic

Ovarian Neoplasms

NCT00058552 2017-03-08

A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer

Genentech, Inc.

Phase 2 Completed
129 enrolled 13 charts
Gynecologic

Ovarian Neoplasms

NCT00096993 2015-06-10

A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Genentech, Inc.

Phase 2 Completed
131 enrolled 11 charts
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT02004093 2014-12-04

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Hoffmann-La Roche

Phase 2 Completed
149 enrolled 20 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡